Accueil 
Nota Bene Cancer V2 Numéro 135 du 10 May 2012 Traitements BREADCRUMB PUBLICATION
A Phase 2 Pharmacodynamic Study of Pre-operative Figitumumab in Patients with Localized Prostate Cancer
Mené sur 16 patients atteints d'un cancer localisé de la prostate (âge médian : 63 ans), cet essai de phase II évalue le figitumumab, un anticorps monoclonal anti IGF-IR
- Clinical Cancer Research, sous presse, 2012 (résumé)
Résumé en anglais :
Purpose: Activation of the insulin-like growth factor 1 receptor (IGF-IR) is implicated in prostate cancer development and progression. This study evaluated biologic and clinical effects of figitumumab, a fully human monoclonal IGF-IR antibody, in patients with localized prostate cancer. Patients and Methods: Eligible patients received figitumumab 20 mg/kg intravenously every 3 weeks for 3 cycles followed by prostatectomy. The primary endpoint was IGF-IR expression inhibition as assessed by immunohistochemistry. Results: Sixteen patients were accrued. Median age was 63 years, median PSA was 7.2 mu g/L (range 2.5-35), clinical stage was T1 in 4 patients and T2 in 12 patients, Gleason score (less than or equal to)7 or greater than 7 in 15 and 1 patients. Two patients received only 1 cycle (patient choice and grade 3 hyperglycemia). A PSA decline from baseline of (greater than or equal to)25% and (greater than or equal to)50% occurred in 15 (94%) and 5 (31%) of patients. Mean figitumumab concentration was 350.4 mu g/ml (26.3-492.8) in plasma and 51.3 mu g/g (27.4-79.6) in prostate tissue. Compared to pre-treatment biopsies, IGF-IR expression decreased in the prostatectomy specimens in 14 of 16 patients. The mean IGF-IR immunohistochemistry visual score was 2.1 (SD=0.6) in biopsy and 1.1 (SD=0.5) in prostatectomy specimens (P less than 0.0001). Androgen receptor expression was also decreased and there was a trend for a decrease in downstream IGF-IR signalling components. Conclusions: Figitumumab is biologically active in prostate cancer. PSA declines in treatment naive patients were observed, potentially mediated by IGF-IR effects on androgen receptor expression. These results support the clinical relevance of IGF-IR signalling in prostate cancer and justify further clinical trials.
Mots clés : Prostate; Traitements (Traitements systémiques : découverte et développement)
Recherche de publications
Widget
Archives
Formulaire d’abonnement
Pour recevoir gratuitement chaque nouveau numéro de Nota Bene Cancer par courriel :
Sources
Pour visualiser l'ensemble des sources alimentant le Nota Bene Cancer :
Foire aux questions
Pour trouver les réponses aux questions que vous vous posez sur Nota Bene Cancer :
